Trevi Therapeutics, Inc. today announced positive interim analysis results of the Phase 2 Cough And NALbuphine (CANAL) trial of its investigational therapy Haduvio™ (nalbuphine ER) in idiopathic pulmonary fibrosis patients (IPF) suffering from chronic cough, establishing proof of concept. Further patient recruitment in the trial will stop based on the strength and consistency of the…
eTurboNews ບົດຄວາມແມ່ນສໍາລັບຜູ້ຈອງເທົ່ານັ້ນ. ການສະໝັກໃຊ້ແມ່ນ ອອນໄລນ໌.
ສະມາຊິກເຂົ້າສູ່ລະບົບທີ່ນີ້ ຄລິກທີ່ນີ້ເພື່ອສະໝັກຟຣີ
ສະມາຊິກເຂົ້າສູ່ລະບົບທີ່ນີ້ ຄລິກທີ່ນີ້ເພື່ອສະໝັກຟຣີ
ສິ່ງທີ່ຄວນເອົາໄປຈາກບົດຄວາມນີ້:
- Further patient recruitment in the trial will stop based on the strength and consistency of the….
- today announced positive interim analysis results of the Phase 2 Cough And NALbuphine (CANAL) trial of its investigational therapy Haduvio™ (nalbuphine ER) in idiopathic pulmonary fibrosis patients (IPF) suffering from chronic cough, establishing proof of concept.
- ການສະໝັກໃຊ້ແມ່ນບໍ່ເສຍຄ່າ.
